<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171080</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489ADE19</org_study_id>
    <nct_id>NCT00171080</nct_id>
  </id_info>
  <brief_title>VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis</brief_title>
  <official_title>A 2 x 5-week Multicenter, Cross-over Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan 80 mg Compared to Irbesartan 150 mg in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy, safety and tolerability of valsartan 80
      mg (with a starting dose of 40 mg) to irbesartan 150 mg (with a starting dose of 75 mg) in
      patients on long-term haemodialysis with mild to moderate increased mean supine systolic
      blood pressure (MSSBP).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in systolic blood pressure after 4 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic blood pressure after 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure less than 100 mmHg with or without symptoms of low blood pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and clinical laboratory abnormal results</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average 24-hour ambulatory blood pressure after 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daytime and nighttime ambulatory blood pressures after 4 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">86</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irbesartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild and moderate hypertension defined by a MSSBP ≥ 140 mmHG and &lt; 180
             mmHG at Visits 1 and 2 for treated and untreated patients

          -  Chronic hemodialysis for at least 6 months prior to Visit 1 as substitution therapy.

          -  If treated with epoetin: patients with a stable hematocrit ≤ 40% (± 5%).

        Exclusion Criteria:

          -  Inability to discontinue angiotensin II receptor blockers (ARBs) safely for a period
             of 1 week, as required by the protocol.

          -  Treatment with more than 3 different compounds for the treatment of hypertension at
             Visit 1.

          -  Atrial fibrillation

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2752</url>
    <description>Results for CVAL489ADE19 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Leidig M, Bambauer R, Kirchertz EJ, Szabã T, Handrock R, Leinung D, Baier M, Schmieder RE. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol. 2008 Jun;69(6):425-32.</citation>
    <PMID>18538118</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Valsartan</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Renal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

